Meropenem pharmacokinetics in the newborn

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3871-3879

  Van Den Anker, John N ^a,b,c   Pokorna, Pavla ^d   Kinzig Schippers, Martina ^e   Martinkova, Jirina ^f   De Groot, Ronald ^g   Drusano, G L ^h   Sorgel, Fritz ^e,i  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Institute for Biomedical and Pharmaceutical Research   (Germany)

^f UNIVERSITY OF HRADEC KRALOVE   (Czech Republic)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ORDWAY RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEWBORN; NEWBORN INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MONTE CARLO METHOD; THIENAMYCINS;

EID: 70349128147     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00351-09     Document Type: Article

References (30)

1. Baker, C. J., M. E. Melish, R. T. Hall, D. T. Casto, U. Vasan, and L. B. Givner. 1992. Intravenous immunoglobulin for the prevention of nosocomial infection in low-birth-weight neonates. N. Engl. J. Med. 327:213-219.
2. Besunder, J. B., M. D. Reed, and J. L. Blumer. 1988. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic- pharmacodynamic interface (part 1). Clin. Pharmacokinet. 14:189-216.
3. Bradley, J. S., M. N. Dudley, and G. L. Drusano. 2003. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr. Infect. Dis. J. 22:982-992.
4. Bradley, J. S., J. B. Sauberan, P. G. Ambrose, S. M. Bhavnani, M. R. Rasmussen, and E. V. Caparelli. 2008. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr. Infect. Dis. J. 27:794-799.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis. 26:1-10.
6. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. University of Southern California, Los Angeles, CA.
7. de Hoog, M., J. N. van den Anker, and J. W. Mouton. 2004. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 43:417-440.
8. de Hoog, M., J. W. Mouton, and J. N. van den Anker. 2003. The use of aminoglycosides in newborn infants, p. 117-140. In I. Choonara, A. J. Nunn, and G. Kearns (ed.), Introduction to paediatric and perinatal drug therapy. Nottingham University Press, Nottingham, United Kingdom.
9. Drukker, A., and J. P. Guignard. 2002. Renal aspects of the term and preterm infant: a selective update. Curr. Opin. Pediatr. 14:175-182.
10. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: the interactions between bug and drug. Nat. Rev. Microbiol. 2:289-300.
11. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
12. Drusano, G. L., K. H. P. Moore, J. P. Kleim, W. Prince, and A. Bye. 2002. Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through the use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob. Agents Chemother. 46:913-916.
13. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
14. Escobar, G. J., T. Zukin, M. S. Usatin, J. Lemesurier, D. Honeychurch, M. A. Armstrong, and B. Folck. 1994. Early discontinuation of antibiotic treatment in newborns admitted to rule out sepsis: a decision rule. Pediatr. Infect. Dis. J. 13:860-866.
15. Fanaroff, A. A., S. B. Korones, L. L. Wright, E. C. Wright, R. L. Poland, C. B. Bauer, J. E. Tyson, J. B. Philipis III, W. Edwards, and J. F. Lucey. 1994. A controlled trial of intravenous immunoglobulin to reduce nosocomial infections in very-low-birth-weight infants. N. Engl. J. Med. 330:1107-1113.
16. Gladstone, I. M., R. A. Ehrenkranz, S. C. Erdberg, and R. S. Baltimore. 1990. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr. Infect. Dis. J. 9:819-825.
17. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Investig. 112:275-285.
18. Klein, J. O., and S. Michael Marcy. 1995. Bacterial sepsis and meningitis, p. 836. In J. S. Remington and J. O. Klein (ed.), Infectious diseases of the fetus & newborn infant. WB Saunders & Company, Philadelphia, PA.
19. Leake, R. D., C. W. Trygstad, and W. Oh. 1976. Inulin clearance in the newborn infant: relationship to gestational and postnatal age. Pediatr. Res. 10:759-762.
20. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD). 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
21. Mouton, J. W., D. J. Touw, A. M. Horrevorts, and A. A. Vinks. 2000. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 39:185-201.
22. Pacifici, G. M., J. Labatia, H. Mulla, and I. Choonara. 2009. Clinical pharmacokinetics of penicillins in the neonate: a review of the literature. Eur. J. Clin. Pharmacol. 65:191-198.
23. Schwartz, G. J., G. B. Haycock, C. M. Edelman, Jr., and A. Spitzer. 1976. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263.
24. Shah, S. S., R. A. Ehrenkranz, and P. G. Gallagher. 1999. Increasing incidence of gram-negative rod bacteremia in a newborn intensive care unit. Pediatr. Infect. Dis. J. 18:591-595.
25. Stoll, B. J., T. Gordon, S. B. Korones, S. Shankaran, J. E. Tyson, C. R. Bauer, A. A. Fanaroff, J. A. Lemons, E. F. Donovan, W. Oh, D. K. Stevenson, R. A. Ehrenkranz, L. A. Papile, J. Verter, and L. L. Wright. 1996. Early onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J. Pediatr. 129:72-80. (Pubitemid 26277249)
26. Tam, V. H., A. N. Schilling, S. Neshat, K. Poole, D. A. Melnick, and E. A. Coyle. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
27. van den Anker, J. N., W. C. Hop, R. De Groot, B. J. van der Heijden, H. M. Broerse, J. Lindemans, and P. J. Sauer. 1994. Effect of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr. Res. 36:578-581.
28. van den Anker, J. N., W. C. Hop, R. C. Schoemaker, B. J. van der Heijden, H. J. Neijens, and R. de Groot. 1995. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. Br. J. Clin. Pharmacol. 40:439-443.
29. van der Heijden, H. J., W. F. Grose, J. J. Ambagtsheer, A. P. Provoost, E. D. Wolff, and J. J. Sauer. 1988. Glomerular filtration rate in the preterm infant: the relation to gestational and postnatal age. Eur. J. Pediatr. 148:24-28.
30. Van Enk, J. G., D. Touw, and H. N. Lafeber. 2001. Pharmacokinetics of meropenem in preterm neonates. Ther. Drug Monitor. 23:198-201.